Spruce Biosciences, Inc. (SPRB)

NASDAQ: SPRB · USD

$42.8

-1.74 (-3.9%)· Recorded snapshot

Market cap	123M
Net income (ttm)	-51.4M
EPS (ttm)	-$36.0
Shares out	2.9M
Volume	73,491.295
Beta	3.54

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -51.4M
EPS (ttm): -$36.0
Market cap: 123M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-106

P25 n/aP50 n/aP75 n/a

ROIC-46.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SPRB indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001683553
Company name	Spruce Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	85209E208
Earnings date	2026-08-12
Earnings time	bmo
Employees	22
Employees change	13
Employees growth	144.44%
Enterprise value	$34.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US85209E2081
Last earnings date	2026-08-12
Last refreshed	2026-11-04
Last stock split date	2025-08-07
Last stock split type	Reverse
Market cap	$123M
Market cap category	Micro-Cap
Options	No
Price	$42.81
Price currency	USD
Sector	Healthcare
Stock price date	2026-11-03
Symbol	SPRB
U.S. state	California
Website	https://sprucebio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-84.21%
FCF / EV yield	-124.28%
FCF yield	-34.76%
P/B ratio	1.41x
Price / tangible book value	1.47x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.3M
ROA	-40.03%
ROA (5Y)	-32.76%
ROCE	-43.45%
ROE	-105.98%
ROE (5Y)	-71.97%
ROIC	-46.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-145,000
Depreciation and amortization	$891,000
EBIT	$-39.9M
EBITDA	$-39M
EPS	$-36.05
FCF per share	$-14.88
Financing cash flow	$122.7M
Free cash flow	$-42.8M
Free cash flow minus SBC	$-46.4M
Gross profit	$-23M
Investing cash flow	$-145,000
Net borrowing	$12.9M
Net cash flow	$79.9M
Net income	$-51.4M
Operating cash flow minus SBC	$-46.3M
Operating income	$-39.9M
Stock-based compensation	$3.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$30.42
Debt / equity	0.09
Interest coverage	-22.23
Long-term assets	$1.7M
Long-term liabilities	$8.2M
Net cash (debt)	$88.6M
Net cash / market cap	72.03%
Net cash growth	508.51%
Net debt / equity	-1.06
Piotroski F-Score	2
Property, plant and equipment	$523,000
Shareholders' equity	$83.7M
Tangible book value	$83.7M
Tangible book value per share	$30.42
Total assets	$102.9M
Total cash	$96.3M
Total debt	$7.7M
Total liabilities	$19.1M
WACC	23.39%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$101.2M
Current liabilities	$11M
Current ratio	9.23
Net working capital	$-3.3M
Quick ratio	8.78
Working capital	$90.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-149.79%
Dividend yield	0%
Shareholder yield	-149.79%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$51.72
1D price change	-3.91%
1M price change	-6.34%
1M total return	-6.34%
1W price change	-6.22%
1W total return	-6.22%
1Y price change	-61.12%
1Y return CAGR	-61.14%
1Y total return	-61.12%
20-day SMA	$43.50
200-day SMA	$55.47
3M price change	-0.05%
3M total return	-0.05%
3Y price change	-49.04%
3Y return CAGR	-20.12%
3Y total return	-49.04%
50-day SMA	$49.55
50-day SMA vs 200-day SMA	50under200
52-week high	$129.00
52-week high date	2025-11-10
52-week low	$38.06
52-week low date	2026-10-14
5Y price change	-87.83%
5Y return CAGR	-34.38%
5Y total return	-87.83%
6M price change	-25.26%
6M total return	-25.26%
After-hours change	1.15%
After-hours close	$42.81
After-hours price	$43.30
All-time high	$2,670.01
All-time high date	2020-11-27
All-time low	$4.28
All-time low date	2025-04-29
Average true range (ATR)	$2.81
Average volume	78.4K
Beta (1Y)	-0.03
Beta (2Y)	-10.92
Beta (5Y)	3.54
Change from 52-week high	-66.81%
Change from 52-week low	12.48%
Change from all-time high	-98.4%
Change from all-time low	901.4%
Change from open	-4.87%
Day's gap	1.01%
Dollar volume	$3.1M
High price	$45.63
Low price	$42.51
Monthly RSI	42.92
Open price	$45.00
Position in 52-week range	9.62%
Premarket change	0%
Premarket close	$42.81
Premarket price	$42.81
Previous close	$44.55
Price vs 150-day SMA	-17.22%
Price vs 20-day SMA	-1.59%
Price vs 200-day SMA	-22.83%
Price vs 50-day SMA	-13.61%
Relative volume	0.94
RSI	43.05
Sharpe ratio	-0.73
Sharpe ratio (3Y)	0.54
Sharpe ratio (5Y)	0.4
Sortino ratio	-0.92
Sortino ratio (3Y)	5.16
Sortino ratio (5Y)	3.4
Volume	73.5K
Weekly RSI	42.17
YTD price change	-50.86%
YTD total return	-50.86%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2M
Float percentage	70.18%
Shares change (QoQ)	77.18%
Shares change (YoY)	149.79%
Shares held by insiders	3.45%
Shares held by institutions	51.06%
Shares outstanding	2.9M
Short % of float	25.89%
Short % of shares	18.17%
Short ratio	5.9 days

Deeper analysis on SPRB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SPRB report

Is a complete SPRB research report available?

No complete published report is available for Spruce Biosciences, Inc. (SPRB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Spruce Biosciences, Inc. (SPRB)

Price

Financial snapshot

Fair-value bridge

Latest news · SPRB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SPRB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SPRB

Frequently asked questions